Smith & Nephew's 2022 performance weighed down by inflation and currency headwinds
The medtech company expects underlying revenue growth of 5–6% in 2023 though its earnings margin will continue to experience negative impacts from increasing commodity prices and wages.
by marketwire, translated by daniel pedersen
Smith & Nephew exited 2022 with a weaker operating profit than anticipated after a year plagued by currency headwinds and increasing costs.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
Get full access for you and your coworkers
Start a free company trial todayRelated articles
Ambu opens up about stalled Russian exit
For subscribers
